Mahshid Toghanian
Primary Care · Patchogue, NYNPI 1710524533
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,798 and has fallen 52.6% since, to $853 in 2025. Among primary care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Abbott$440
- Novo Nordisk$334
- Sumitomo Pharma America, Inc.$275
- Corium, LLC$272
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $1,359 |
| Otsuka America Pharmaceutical, Inc. | 24 | $1,181 |
| Abbott | 3 | $440 |
| Novo Nordisk | 18 | $334 |
| Sumitomo Pharma America, Inc. | 6 | $275 |
| Corium, LLC | 11 | $272 |
| GSK | 9 | $187 |
| Sanofi-aventis U.S. LLC | 4 | $172 |
| Evoke Pharma, Inc. | 3 | $155 |
| Lundbeck LLC | 7 | $145 |
| Ardelyx, Inc. | 6 | $125 |
| Merck | 6 | $114 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Amgen | 4 | $89 |
| Cumberland Pharmaceuticals, Inc. | 1 | $79 |
| Lilly USA, LLC | 4 | $76 |
| Novartis | 4 | $67 |
| Johnson & Johnson | 3 | $64 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| AbbVie | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $38 |
| Bayer | 1 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $31 |
| Neurelis, Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| UCB, Inc. | 1 | $26 |
| Renalytix AI, Inc. | 1 | $24 |
| Pfizer | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Vistapharm, Inc. | 1 | $14 |
| Forte Bio-pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$859
- BREZTRI$498
- FREESTYLE LIBRE 3$319
- FARXIGA$250
- AIRSUPRA$221
- FreeStyle Libre 2$121
- GIMOTI$121
- SOLIQUA 100/33$118
- ADLARITY$118
- LOKELMA$111
- GEMTESA$106
How this compares
$5,714 in reported general payments places this provider in the 95th percentile of 239 primary care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 34 | $47,057 |
| RybelsusSemaglutide | 21 | $38,645 |
| OzempicSemaglutide | 16 | $16,123 |
| EliquisApixaban | 11 | $14,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,300 |
| GemtesaVibegron | 14 | $7,739 |
| Levothyroxine Sodium | 99 | $2,108 |
| Nifedipine ErNifedipine | 31 | $1,970 |
| Midodrine Hcl | 17 | $1,383 |
| Metoprolol Succinate | 120 | $1,284 |
| Labetalol Hcl | 26 | $1,010 |
| Gabapentin | 51 | $922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $856 |
| Atorvastatin Calcium | 125 | $738 |
| Tamsulosin Hcl | 48 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $334 | $54,76837 claims |
| AstraZenecaFarxiga | $1,359 | $47,05734 claims |
| PfizerEliquis | $24 | $14,72111 claims |
| GSKTrelegy Ellipta | $187 | $11,30016 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $275 | $7,73914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 primary care providers in New York.
Other primary care in Patchogue
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.